Improved memory for reward cues following acute buprenorphine administration in humans. 2015

Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
Department of Psychiatry University of Cape Town South Africa; Department of Psychology University of Toronto Canada.

In rodents, there is abundant evidence for the involvement of the opioid system in the processing of reward cues, but this system has remained understudied in humans. In humans, the happy facial expression is a pivotal reward cue. Happy facial expressions activate the brain's reward system and are disregarded by subjects scoring high on depressive mood who are low in reward drive. We investigated whether a single 0.2mg administration of the mixed mu-opioid agonist/kappa-antagonist, buprenorphine, would influence short-term memory for happy, angry or fearful expressions relative to neutral faces. Healthy human subjects (n38) participated in a randomized placebo-controlled within-subject design, and performed an emotional face relocation task after administration of buprenorphine and placebo. We show that, compared to placebo, buprenorphine administration results in a significant improvement of memory for happy faces. Our data demonstrate that acute manipulation of the opioid system by buprenorphine increases short-term memory for social reward cues.

UI MeSH Term Description Entries
D008297 Male Males
D008570 Memory, Short-Term Remembrance of information for a few seconds to hours. Immediate Recall,Memory, Immediate,Working Memory,Memory, Shortterm,Immediate Memories,Immediate Memory,Immediate Recalls,Memories, Immediate,Memories, Short-Term,Memories, Shortterm,Memory, Short Term,Recall, Immediate,Recalls, Immediate,Short-Term Memories,Short-Term Memory,Shortterm Memories,Shortterm Memory,Working Memories
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D003463 Cues Signals for an action; that specific portion of a perceptual field or pattern of stimuli to which a subject has learned to respond. Cue
D005149 Facial Expression Observable changes of expression in the face in response to emotional stimuli. Face Expression,Expression, Face,Expression, Facial,Face Expressions,Facial Expressions
D005239 Fear The affective response to an actual current external danger which subsides with the elimination of the threatening condition. Threat Cues,Threat Sensitivity,Cue, Threat,Fears,Sensitivity, Threat,Threat Cue,Threat Sensitivities
D005260 Female Females
D006240 Happiness Highly pleasant emotion characterized by outward manifestations of gratification. Gladness,Joy,Happinesses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
July 1995, The Journal of pharmacology and experimental therapeutics,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
January 1988, Psychopharmacology,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
September 2004, Psychoneuroendocrinology,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
January 2018, Nephron,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
November 2000, Experimental and clinical psychopharmacology,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
October 2004, European journal of gastroenterology & hepatology,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
September 2017, Pakistan journal of pharmaceutical sciences,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
June 2008, American journal of veterinary research,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
April 2000, Nature neuroscience,
Supriya Syal, and Jonathan Ipser, and David Terburg, and Mark Solms, and Jaak Panksepp, and Susan Malcolm-Smith, and Peter A Bos, and Estrella R Montoya, and Dan J Stein, and Jack van Honk
July 2007, Human psychopharmacology,
Copied contents to your clipboard!